Quinolones for the treatment and prophylaxis of tuberculosis. NLM AIDSLINE Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Quinolones for the treatment and prophylaxis of tuberculosis.

Ann Pharmacother. 1996 Sep;30(9):1020-2. Unique Identifier : AIDSLINE MED/97030937
Kaplan JA; Krieff DM; Department of Pharmacy, Long Island Jewish Medical Center, NY; 11040, USA.

Abstract: Quinolones possess enormous potential as antimycobacterial agents, and have been proven to have excellent in vitro activity against M. tuberculosis, as well as limited in vivo efficacy. These drugs appear to be safe and well tolerated even when taken for an extended period. This is important considering that one of the most significant factors contributing to resistance is compliance. Quinolones exhibit great promise for initial treatment and retreatment of MDRTB, a rapidly growing problem, as well as for prevention. They have shown to be as effective as some of the first-line agents currently used in treating TB. There appears to be overwhelming need to further study these agents and determine their role in the treatment of TB. In the future, quinolones may emerge as first-line therapy for TB.
Keywords: Anti-Infective Agents, Fluoroquinolone/PHARMACOKINETICS/ *THERAPEUTIC USE AIDS-Related Opportunistic Infections Human Randomized Controlled Trials Tuberculosis/*DRUG THERAPY/METABOLISM/*PREVENTION & CONTROL Tuberculosis, Multidrug-Resistant/*DRUG THERAPY/METABOLISM JOURNAL ARTICLEKWDanti-infectiveagents,fluoroquinolone/pharmacokinetics/KWDtherapeuticuseaids-relatedopportunisticinfectionshumanrandomizedcontrolledtrialstuberculosis/KWDdrugtherapy/metabolism/KWDprevention&controltuberculosis,multidrug-resistant/KWDdrugtherapy/metabolismjournalarticle
97033030
M9730698

Copyright © 1997 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .